Targeted therapy for hepatocellular carcinoma: Challenges and opportunities - PubMed (original) (raw)
Review
Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
Shuzhen Chen et al. Cancer Lett. 2019.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, which ranks as the sixth of cancer-related death. Despite the emergence of targeted therapy, advanced-stage HCC remains largely incurable due to low response rate and therapeutic resistance. In this review, we mainly focused on the current progression of multi-kinase inhibitors and immunotherapies in the treatment of HCC. We highlight the mechanism underlying the ineffectiveness of these targeted therapies, including oncogenic alterations in driver genes and downstream pathways, high heterogeneity of HCC, and the mutual interaction of tumor microenvironment that promotes therapeutic resistance. We also discussed how these previous studies suggested for future therapeutic strategies. Besides, the complexity of HCC heterogeneity and cancer revolution need to be recognized in personalized therapy. Establishment of a drug screening system and identification of biomarkers of response is also in urgent need to overcome drug resistance. Meanwhile, a combination of targeted therapies could also be explored as a promising strategy in the future.
Keywords: Drug resistance; Hepatocellular carcinoma (HCC); Immunotherapy; Multi-kinase inhibitors (MKIs).
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
- Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E, Cecchin E, Guardascione M, Foltran L, Di Raimo T, Angelini F, D'Andrea M, Toffoli G. De Mattia E, et al. World J Gastroenterol. 2019 Aug 7;25(29):3870-3896. doi: 10.3748/wjg.v25.i29.3870. World J Gastroenterol. 2019. PMID: 31413525 Free PMC article. Review. - Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP, Huang YP, Luo WX, Deng WY, Liu CQ, Xu LB, Liu C. Zhang FP, et al. World J Gastroenterol. 2020 Jan 14;26(2):134-153. doi: 10.3748/wjg.v26.i2.134. World J Gastroenterol. 2020. PMID: 31969776 Free PMC article. - New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. Dal Bo M, et al. Drug Resist Updat. 2020 Jul;51:100702. doi: 10.1016/j.drup.2020.100702. Epub 2020 Apr 19. Drug Resist Updat. 2020. PMID: 32371296 Review. - Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.
Neureiter D, Stintzing S, Kiesslich T, Ocker M. Neureiter D, et al. World J Gastroenterol. 2019 Jul 7;25(25):3136-3150. doi: 10.3748/wjg.v25.i25.3136. World J Gastroenterol. 2019. PMID: 31333307 Free PMC article. Review. - Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions.
Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Hilmi M, et al. J Immunother Cancer. 2019 Nov 29;7(1):333. doi: 10.1186/s40425-019-0824-5. J Immunother Cancer. 2019. PMID: 31783782 Free PMC article. Review.
Cited by
- Construction of cuproptosis-related lncRNAs/mRNAs model and prognostic prediction of hepatocellular carcinoma.
Tang L, Wang T, Li W, Yu S, Yao S, Cheng H. Tang L, et al. Am J Cancer Res. 2022 Oct 15;12(10):4693-4707. eCollection 2022. Am J Cancer Res. 2022. PMID: 36381337 Free PMC article. - A 3D Tumor-Mimicking In Vitro Drug Release Model of Locoregional Chemoembolization Using Deep Learning-Based Quantitative Analyses.
Liu X, Wang X, Luo Y, Wang M, Chen Z, Han X, Zhou S, Wang J, Kong J, Yu H, Wang X, Tang X, Guo Q. Liu X, et al. Adv Sci (Weinh). 2023 Apr;10(11):e2206195. doi: 10.1002/advs.202206195. Epub 2023 Feb 15. Adv Sci (Weinh). 2023. PMID: 36793129 Free PMC article. - HCC and Molecular Targeting Therapies: Back to the Future.
Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. Rinaldi L, et al. Biomedicines. 2021 Sep 28;9(10):1345. doi: 10.3390/biomedicines9101345. Biomedicines. 2021. PMID: 34680462 Free PMC article. Review. - Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes.
Chakraborty S, Dlie ZY, Chakraborty S, Roy S, Mukherjee B, Besra SE, Dewanjee S, Mukherjee A, Ojha PK, Kumar V, Sen R. Chakraborty S, et al. Mol Ther Nucleic Acids. 2020 Jun 5;20:34-49. doi: 10.1016/j.omtn.2020.01.034. Epub 2020 Feb 5. Mol Ther Nucleic Acids. 2020. PMID: 32146417 Free PMC article. - Integrated Bioinformatic Analysis Reveals the Oncogenic, Survival, and Prognostic Characteristics of TPX2 in Hepatocellular Carcinoma.
Zhang W, Dong J, Wu Y, Liang X, Suo L, Wang L. Zhang W, et al. Biochem Genet. 2024 Jun 4. doi: 10.1007/s10528-024-10840-3. Online ahead of print. Biochem Genet. 2024. PMID: 38833082
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical